A further investment of up to Rs 160 crore is expected to be completed by March, 2023. The total investment will translate into ~80.3% of equity share capital in Strand on a fully diluted basis.
Strand was incorporated in India on 06 October 2000. Strand is a pioneer of genomic testing in India with bioinformatics software and clinical research solutions to healthcare providers including clinicians, hospitals, medical devices manufacturers and pharmaceutical companies.
Strand's turnover was Rs 88.70 crore, Rs 109.84 crore and Rs 96.60 crore, and Net Profit (Loss) of Rs 8.48 crore, Rs (25.04) crore and Rs (21.66) crore in FY 2021, FY 2020 and FY 2019 respectively.
The aforesaid investment is part of group's digital health initiatives, to foster affordable access to world class technology and innovation led healthcare ecosystem in India.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
